Li-rnai involved li suppression in cancer immunotherapy

C - Chemistry – Metallurgy – 12 – N

Patent

Rate now

  [ 0.00 ] – not rated yet Voters 0   Comments 0

Details

C12N 5/10 (2006.01) A61K 31/713 (2006.01) A61K 35/14 (2006.01) A61P 35/00 (2006.01) A61P 37/02 (2006.01) C07H 21/02 (2006.01) C12N 15/11 (2006.01) C12N 15/63 (2006.01) C12N 15/85 (2006.01) A61K 48/00 (2006.01)

Patent

CA 2680600

Provided are compositions and methods involving the inhibition of Ii expression in cells for the purpose of altering antigen presentation pathways. Human Ii-RNAi constructs that effectively inhibit Ii expression in human cancer cells have been generated. The combination of different Ii-RNAi constructs that target different positions of Ii mRNA has a synergistic effect on Ii inhibition. Furthermore, specific promoters for driving Ii-RNAi expression are critical for the activity of Ii-RNAi in different types of cells. Active Ii-RNAi sequences were cloned into plasmids in which Ii-RNAi sequences are driven by either a CMV or an EF-1.alpha.; promoter. Compositions and methods are disclosed for inhibiting Ii and treating cancer. Provided are siRNAs and expression constructs comprising DNA sequences which encode siRNAs effective to inhibit Ii expression, cells containing such DNA constructs or siRNAs, and methods for use of the same.

L'invention concerne des compositions et des méthodes impliquant l'inhibition de l'expression de la protéine Ii dans des cellules afin d'altérer des voies de présentation d'antigènes. Des constructions Ii-ARNi humaines qui inhibent efficacement l'expression de Ii dans des cellules cancéreuses humaines ont été générées. La combinaison de différentes constructions Ii-ARNi qui ciblent différentes positions d'ARNm de Ii a un effet synergique sur l'inhibition de Ii. De plus, des promoteurs spécifiques pour commander l'expression de Ii-ARNi sont essentiels pour l'activité de Ii-ARNi dans différents types de cellules. Des séquences Ii-ARNi actives ont été clonées en plasmides dans lesquels les séquences Ii-ARNi sont commandées par un promoteur CMV ou EF-1.alpha.. L'invention concerne également des compositions et des méthodes qui permettent d'inhiber la protéine Ii et de traiter le cancer. L'invention concerne en outre des ARNsi et des constructions d'expression comprenant des séquences ADN qui codent des ARNsi efficaces pour inhiber l'expression de la protéine Ii, des cellules contenant lesdites constructions ADN ou les ARNsi, et des méthodes d'utilisation de celles-ci.

LandOfFree

Say what you really think

Search LandOfFree.com for Canadian inventors and patents. Rate them and share your experience with other people.

Rating

Li-rnai involved li suppression in cancer immunotherapy does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Li-rnai involved li suppression in cancer immunotherapy, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Li-rnai involved li suppression in cancer immunotherapy will most certainly appreciate the feedback.

Rate now

     

Profile ID: LFCA-PAI-O-1882096

  Search
All data on this website is collected from public sources. Our data reflects the most accurate information available at the time of publication.